Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penetration of Cubicin and Fosfomycin into skeletal muscle and subcutaneous adipose tissue in necrotizing soft tissue infections
2007-005399-15Phase 4Terminated
- Sponsor
- Medical University of Graz
- Start
- Feb 2010
- Modality
- Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daptomycin and fosfomycin in necrotizing skin infection (NSTI), sponsored by Medical University of Graz. Primary endpoint: Pharmacokinetic parameters of daptomycin and fosfomycin in skeletal muscle and subcutaneous adipose tissue. Started Feb 2010; status: terminated.
02
Drugs
daptomycinfosfomycin
03
Conditions
necrotizing skin infection (NSTI)
Beyond the preview
Go deeper on 2007-005399-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005399-15.